Monitoring

Lifelong risk of another de novo bladder tumour developing requires monitoring, primarily by cystoscopy.

Non-muscle-invasive bladder cancer

Monitoring is based on the risk category.

  • Low-risk: patients have cystoscopy at 3 months because early recurrence is a poor prognostic sign.​[48][153]​​​​ Subsequent frequency and duration of cystoscopy and imaging follow-up is informed by the individual patient's risk and necessitates shared decision-making.[41][48] Discontinuation of cystoscopy or a less invasive method of surveillance should be considered.[48] Recurrence after 5 recurrence-free years is low among patients with low-risk disease.

  • Intermediate risk: recommendations vary. American Urological Association guidelines suggest upper tract imaging at one to two year intervals for patients with intermediate-risk bladder cancer.[41] European Association of Urology guidelines recommend that intermediate-risk patients receive cystoscopy and urine cytology at 3 months, then every 6 months for 2 years, followed by annual cystoscopy for up to 10 years.[44][48]​​​ Upper tract imaging should be considered every 1-2 years.

  • High-risk: patients have cystoscopy and urine cytology every 3 months for 2 years, then every 6 months for years 3 and 4, then annually in the absence of recurrence.[41] Upper tract imaging should be considered every 1-2 years.[41]

Muscle-invasive disease

Involves abdominal/pelvic/chest CT or MRI (every 6-12 months for 2-3 years, then annually) and laboratory assessment (every 3-6 months for 2-3 years, then annually).[111]​ Upper tract imaging, FDG-PET/CT, and cytology may also be indicated.[44]

Regular cystoscopy is required for muscle-invasive disease treated with bladder-sparing modalities (every 3 months for 2 years, then every 6 months for 2 years, then annually until at least year 10).[44][54]​ 

Monitoring for metastatic disease includes regular chest/abdominal/pelvic CT (every 3-6 months, and if new symptoms or clinical changes occur) or FDG-PET/CT and blood tests, with cystoscopy, upper tract imaging, and urine cytology as clinically indicated.[44]

Use of this content is subject to our disclaimer